Table 3 Odds ratios for colon cancer by dose, frequency, and duration of exposure to celecoxib, rofecoxib, aspirin, and ibuprofen.
Compounda | Dose | Cases | Controls | Frequency of Use | Multivariate ORb(95% CI) |
|---|---|---|---|---|---|
N (%) | |||||
None | 0 | 236 (72) | 352 (54) | None | |
Celecoxib | 200 mg | 8 (2) | 27 (4) | Daily | 0.35 (0.18–0.93) |
Rofecoxib | 25 mg | 7 (2) 26 (4) | Daily | 0.32 (0.12–0.83) | |
Aspirin | 325 mg | 5 (2) | 14 (2) | 1–2 weekly | 0.87 (0.24–3.17) |
4 (1) | 8 (1) | 3–6 weekly | 0.73 (0.20–2.67) | ||
13 (4) | 66 (10) | Daily | 0.22 (0.12–0.41) | ||
trend (p < 0.05) | |||||
Ibuprofen | 200 mg | 7 (2) | 17 (3) | 1–2 weekly | 0.67 (0.26–1.69) |
2 (1) | 12 (2) | 3–6 weekly | 0.18 (0.02–1.50) | ||
4 (1) | 39 (6) | Daily | 0.19 (0.07–0.49) | ||
trend (p < 0.01) | |||||